Viatris Inc. VTRS
19.91 USD +0.94 (+4.96%)
At closeNov 9, 2026, 5:48 AM EST
20.23 +0.32 +1.60%
Pre-market · Nov 9, 5:48 AM ET
18.80 Day range 19.94
9.99 52-week range 19.96
- YTD
- +59.92%
- 1 year
- +96.74%
News
zacks.com Viatris Q3 Earnings Beat on Stronger Margins, Revenues Fall Y/Y VTRS beats Q3 earnings estimates on stronger margins and raises 2026 earnings guidance, despite revenue miss and persistent supply constraints.
benzinga.com Viatris Q3 2026 Earnings Call Transcript Viatris (NASDAQ:VTRS) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
zacks.com Viatris (VTRS) Q3 Earnings Beat Estimates Viatris (VTRS) came out with quarterly earnings of $0.71 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.67 per share a year ago.
benzinga.com Viatris Raises FY2026 Adj EPS Guidance from $2.45-$2.49 to $2.56-$2.63 vs $2.51 Est; Narrows FY2026 Sales Guidance from $14.550B-$14.950B to $14.700B-$14.900B vs $14.788B Est Viatris (NASDAQ:VTRS) raises FY2026 Adj EPS guidance from $2.45-$2.49 to $2.56-$2.63 vs $2.51 analyst estimate. Narrows FY2026 sales outlook from $14.550 billion-$14.950 billion to $14.700…
prnewswire.com Viatris Reports Third-Quarter 2026 Financial Results Delivers Total Revenues of $3.75 Billion, U.S. GAAP Net Loss of $325 Million and Adjusted EBITDA of $1.20 Billion Receives Regulatory Approval for RYZUMVI® for Presbyopia in the U.S. and WAKIX® in…
zacks.com Viatris (VTRS) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures Evaluate the expected performance of Viatris (VTRS) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key…
prnewswire.com Viatris Announces Quarterly Dividend PITTSBURGH, Nov. 4, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that on November 2, 2026, its Board of Directors declared a quarterly dividend of…
zacks.com Viatris Gears Up to Report Q3 Earnings: Is a Beat in the Cards? VTRS heads into Q3 earnings with new product growth, regional sales trends and supply challenges shaping its outlook.
benzinga.com Viatris Subsidiary Peach Purchaser Sub Commences Tender Offer To Acquire Pacira Biosciences For $36.50/Shr Viatris Inc. ("Viatris") (NASDAQ:VTRS), a global healthcare company, today announced that Peach Purchaser Sub Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, has commenced a tender offer to
benzinga.com Piper Sandler Maintains Neutral on Viatris, Raises Price Target to $14 Piper Sandler analyst David Amsellem maintains Viatris (NASDAQ:VTRS) with a Neutral and raises the price target from $13 to $14.
benzinga.com JP Morgan Maintains Neutral on Viatris, Raises Price Target to $20 JP Morgan analyst Chris Schott maintains Viatris (NASDAQ:VTRS) with a Neutral and raises the price target from $18 to $20.
benzinga.com Viatris Receives FDA Approval For RYZUMVI To Treat Presbyopia In Adults Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI® (phentolamine ophthalmic solution 0.75%) for the…
benzinga.com Deal Dispatch: Uber Buys ezCater For $2.3B, Skydance Takes Over Warner Bros., True Food Kitchen Bankruptcy Major M&A deals this week include Viatris buys Pacira BioSciences, TowneBank acquires blueharbor, Energy Transfer buys Vacquero Midstream.stocksdownunder.com Viatris (NDQ:VTRS): Meet The Company Behind Viagra! But Can Yesterday’s Blockbuster Still Build Tommorrow’s Returns and How? Yes, Viatris (NDQ:VTRS) is the company behind Viagra amongst many other of the world's best known medicines. In many cases ...
stocksdownunder.com Rocket Lab (NASDAQ:RKLB) Stock Surges 15% Ahead of Earnings: Can Neutron Deliver? Rocket Lab (RKLB) stock surged 15.39% ahead of November 9 earnings. Here's what investors should watch in Q3 results and the ...
- finance.sina.com.cn ADPV前十大重仓股占比47.062%，第一大重仓股为VTRS 其中，第一大重仓股为VTRS，持仓占比5.6201%；第二大重仓股为Roivant Sciences Ltd ORD，占比5.4251%；第三大重仓股为慧与，占比5.0130%。 此外，前十大重仓股还包括Centene Corp、Central Bancompany, Inc. ORD、 美国豪斯特酒店 、Ringcentral Inc. Class A、阿帕奇公司、Avantor, Inc.
finance.sina.com.cn NuShares ESG Small-Cap ETF前十大重仓股占比10.3721%，第一大重仓股为VTRS 其中，第一大重仓股为VTRS，持仓占比1.2802%；第二大重仓股为Nextpower Inc ORD，占比1.1573%；第三大重仓股为 美国豪斯特酒店 ，占比1.1171%。ad-hoc-news.de Viatris stock: Q3 revenue holds steady as guidance rises Total revenue for the quarter ended September 30 was 3.75 billion US dollars, compared with 3.76 billion US dollars a year ...
crowdfundinsider.com SpaceX ($SPCX) Q4 Surge Expected by Elon Musk as Tesla ($TSLA) Eyes Robotics Growth Elon Musk recently outlined an aggressive near-term revenue outlook for SpaceX (NASDAQ: SPCX) during a discussion at the ...
crowdfundinsider.com European Union Introduces Task Force to Counter Cryptocurrency based Sanctions Evasion by Russia The European Union has established a specialized Crypto Sanctions Task Force to detect and disrupt efforts to bypass its ...